QuantaFlo HD: blood flow at the finger during a forced expiration
Study summary
The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.
Eligibility
Sex
ALL
Min age
22 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Male and female adult (≥ age 22) subjects with a minimum of 1 of the following:
* A history of Cardiovascular Diseasei or PAD
* Recorded history of at least two of the following
* Hypertension
* Diabetes
* Hyperlipidemia
Exclusion Criteria:
* Unable to safely perform a forced expiration, or unable to obtain a technically adequate FE test result
* Subjects with a pacemaker or ICD with pacemaker function
* Terminal advanced illness
* Recent cardiothoracic surgery (within 12 months)
* Retinal eye disease with anticoagulants
* History of eye surgery, within 90 days
* Uncontrolled hypertension \>180 mmHg systolic pressure or \>100 mmHg diastolic pressure
* Subjects with severe tremors
Primary outcome measure(s)
Sensitivity and Specificity — From enrollment to the end of treatment is up to 1 week Evaluate the sensitivity and specificity of QuantaFlo HD test results to GLS findings.
Trial sites (1)
Facility
City
Region
Status
Pima Heart and Vascular
Tucson
Arizona
Recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.